This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients

This study has been withdrawn prior to enrollment.
(did not enroll a patient)
Information provided by (Responsible Party):
Marc Scheetz, Midwestern University Identifier:
First received: January 3, 2012
Last updated: March 16, 2016
Last verified: March 2016
Ceftazidime is a broad spectrum cephalosporin with high activity against a variety of Gram-negative pathogens, including Pseudomonas aeruginosa. An open-label study of intravenous ceftazidime pharmacokinetics will be performed in patients undergoing intermittent hemodialysis at Northwestern Memorial Hospital to determine the clearance of ceftazidime in high flux hemodialysis.

Condition Intervention Phase
Renal Failure Other: pharmacokinetic monitoring Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients

Resource links provided by NLM:

Further study details as provided by Marc Scheetz, Midwestern University:

Primary Outcome Measures:
  • Determine clearance of ceftazidime in hemodialysis [ Time Frame: time 0 = end of infusion) up to 72 hours ]
    Serial blood draws will be performed at the following times in hours (time 0 = end of infusion): the time immediately before hemodialysis, 0.5, 4, and immediately before the next dose of ceftazidime. Any extra blood from samples drawn by the primary provider per routine care during the study period will also be considered for capture if it would routinely be discarded. The blood draws for this study will occur over a period of 72 hours (i.e. until the day of the following hemodialysis session).

Enrollment: 0
Study Start Date: January 2012
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
pharmacokinetic monitoring
Other: pharmacokinetic monitoring
pharmacokinetic monitoring
Other Name: Fortaz


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Eligible patients are male or female adults ≥18 years of age with an expected hospital stay of at least 48 hours, who have end-stage renal disease and been receiving intermittent hemodialysis for at least 90 days.
  • Eligible patients will additionally have either central or peripheral intravenous access, and will already be prescribed ceftazidime per their primary providers.
  • Written informed consent in a form approved by Northwestern Memorial Hospital, Northwestern University Institutional Review Board, and Midwestern University Institutional Review Board will be completed by the patient prior to enrollment.

Exclusion Criteria:

  • Patients that only receive one dose of ceftazidime in total
  • Patients with potentially altered pharmacokinetic parameters (pregnant patients, burn patients, and those that are morbidly obese (BMI ≥ 40 kg/m2).
  • Not meeting inclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01507532

United States, Illinois
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Midwestern University
Principal Investigator: Marc H Scheetz, PharmD Midwestern University
  More Information

Responsible Party: Marc Scheetz, Associate Professor, Midwestern University Identifier: NCT01507532     History of Changes
Other Study ID Numbers: STU00056702
Study First Received: January 3, 2012
Last Updated: March 16, 2016

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Anti-Bacterial Agents
Anti-Infective Agents processed this record on August 22, 2017